LA JOLLA, CA, October 4, 2012 – Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the pricing of its initial public offering of 11,250,000 shares of its common stock at $4.00 per share. Regulus has also granted the underwriters a 30-day option to purchase up to an additional 1,687,500 shares at the initial public offering price to cover overallotments, if any. Regulus’ common stock is scheduled to begin trading on The NASDAQ Global Market on October 4, 2012 under the symbol “RGLS.”
Lazard Capital Markets LLC, Cowen and Company, LLC and BMO Capital Markets are acting as joint book-running managers for the offering. Needham & Company and Wedbush PacGrow Life Sciences are acting as co-managers.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on October 4, 2012.
The offering is being made only by means of a prospectus, copies of which may be obtained from Lazard Capital Markets LLC, Attn: Syndicate Department, 30 Rockefeller Plaza, 48th Floor, New York, NY 10020, Telephone: (800) 542-0970; from Cowen and Company, LLC (c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, Telephone: (631) 274-2806, Fax: 631-254-7140); or from BMO Capital Markets, Attention: Equity Syndicate Department, 3 Times Square New York, NY 10036, Telephone: (800) 414-3627, E-mail: firstname.lastname@example.org.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) and Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is using a mature therapeutic platform based on technology that has been developed over 20 years. Regulus is advancing microRNA therapeutics toward clinical development in several areas, including oncology, fibrosis, hepatitis C and metabolic diseases.
Russo Partners LLC